Search Results
Your search for The ASCO Post matches 17639 pages
Showing 16751 - 16800Study Identifies New Pathway for Stalling BRCA-Mutated Tumor Growth in Mice and Human Cells
Inhibiting the action of a particular enzyme dramatically slows the growth of tumor cells tied to BRCA1 and BRCA2 genetic mutations that are closely tied to breast and ovarian cancers, according to researchers at New York University (NYU) Langone Medical Center. Senior investigator Agnel Sfeir,...
FDA Approves Palbociclib in Combination With Letrozole for Advanced Breast Cancer
The U.S. Food and Drug Administration has granted accelerated approval to palbociclib (Ibrance) in combination with letrozole for the treatment of postmenopausal women with estrogen receptor–positive, HER2-negative metastatic breast cancer who have not yet received an endocrine-based therapy. ...
Study Sheds New Light on Syndrome Associated With Aggressive Pediatric Cancer
A new study involving researchers at The University of Nottingham has revealed how children with an aggressive cancer predisposition syndrome experience a never-before- seen flood of mutations in their disease in very short periods of time. The findings were published by Shlien et al in Nature...
Study Finds Biologic Markers Associated With High-Risk Pancreatic Lesions
Pancreatic cancer affects approximately 46,000 people each year in the United States, and ranks fourth among the leading causes of cancer-related deaths. Only about 6% of individuals with pancreatic cancer will live 5 years after their diagnosis. One reason for this high mortality rate is the lack...
FDA Grants Priority Review for Trabectedin for the Treatment of Patients With Advanced Soft-Tissue Sarcoma
Janssen Research & Development, LLC, announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for trabectedin to treat patients with advanced soft-tissue sarcoma, including liposarcoma and leiomyosarcoma subtypes, who have...
FDA Grants Breakthrough Therapy Designation to MPDL3280A for Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Genentech’s investigational cancer immunotherapy MPDL3280A for the treatment of PD-L1–positive non–small cell lung cancer (NSCLC) that has progressed during or after platinum-based...
California Primary Care Physicians Struggle to Adapt to Breast Density Law, Study Shows
Ten months after California legislators enacted a controversial law mandating that radiologists notify women if they have dense breast tissue, University of California (UC), Davis researchers have found that half of primary care physicians are still unfamiliar with the law, and many don't feel...
High-Risk Prostate Cancer Detection More Likely With Targeted MRI/Ultrasound Fusion Technique Than With Standard Biopsy
Targeted biopsy using new fusion technology that combines magnetic resonance imaging (MRI) with ultrasound is more effective than standard biopsy in detecting high-risk prostate cancer, according to a study by Siddiqui et al published in JAMA. More than 1,000 men participated in the research at the ...
Researchers Pinpoint Two Genes That Trigger Most Severe Form of Ovarian Cancer
Researchers at University of North Carolina School of Medicine have created the first mouse model of the most aggressive form of ovarian cancer and found a potential route to better treatments and much-needed diagnostic screens. Led by Terry Magnuson, PhD, the Sarah Graham Kenan Professor and Chair ...
Inherited Gene Variation Helps Explain Drug Toxicity in ALL Patients of East Asian Ancestry
Scientists at St. Jude Children's Research Hospital have discovered about 10% of young leukemia patients of East Asian ancestry inherit a gene variation that is associated with reduced tolerance of a drug that is indispensable for curing acute lymphoblastic leukemia (ALL), the most common childhood ...
Protein-Based Therapy Shows Promise Against Resistant ALL in Preclinical Study
Chemotherapy resistance is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Now researchers at Children’s Hospital Los Angeles (CHLA) have designed and developed a new protein-based therapy that may prove highly...
FDA Approves New Indication for Ibrutinib in Waldenström's Macroglobulinemia
The U.S. Food and Drug Administration (FDA) today expanded the approved use of ibrutinib (Imbruvica) for patients with Waldenström’s macroglobulinemia, a rare, indolent type of B-cell lymphoma. Ibrutinib is the first therapy indicated specifically for Waldenström’s...
Study Uncovers Range of Molecular Alterations in Head and Neck Squamous Cell Carcinomas, New Potential Drug Targets
Investigators with The Cancer Genome Atlas (TCGA) Research Network have discovered genomic differences—with potentially important clinical implications—in human papillomavirus (HPV)-associated head and neck cancers. These findings were reported in Nature. The researchers also uncovered ...
Testosterone Therapy May Help Some Men With Castration-Resistant Prostate Cancer
According to researchers at the Johns Hopkins Kimmel Cancer Center, testosterone, which is generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers. The hormone may also reverse resistance to testosterone-blocking drugs used to treat prostate...
Supplemental New Drug Application Submitted for Carfilzomib for Relapsed Multiple Myeloma
Amgen and its subsidiary Onyx Pharmaceuticals, Inc, announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for carfilzomib (Kyprolis) to seek approval for the treatment of patients with relapsed multiple myeloma who have received at...
Analysis of Unexplored Part of Human Genome May Lead to Cancer Biomarker Development
A new analysis opens the door to the discovery of thousands of potential new cancer biomarkers, according to a recent study by Iyer et al published in Nature Genetics. Long Noncoding RNA Researchers at the University of Michigan Comprehensive Cancer Center analyzed the global landscape of long...
New Breast Exam Nearly Quadruples Detection of Invasive Breast Cancers When Added to Screening Mammography in Women With Dense Breast Tissue
A new breast imaging technique developed at Mayo Clinic nearly quadruples detection rates of invasive breast cancers in women with dense breast tissue, according to the results of a study published by Rhodes et al in the American Journal of Roentgenology. What Is MBI? Molecular breast imaging...
Head and Neck Cancers in Young Adults More Likely to Be a Result of Inherited Factors
Data from 25 case-control studies and separate analyses show that head and neck cancers in young adults are more likely to occur as a result of inherited factors rather than lifestyle factors, such as smoking or drinking alcohol, according to a new study by Toporcov et al published in the...
Researchers Identify Potential Treatment Targeting Proliferation Pathway in Some Aggressive Tumors
Researchers from the Massachusetts General Hospital (MGH) Cancer Center and Boston University School of Medicine (BUSM) have identified a potential treatment targeting a pathway by which several aggressive tumors maintain their ability to proliferate, according to a study by Flynn et al published...
Long-Term Use of Hormonal Contraceptives Could Lead to Increased Risk of Brain Tumors
Taking a hormonal contraceptive for at least 5 years is associated with a possible increase in women’s risk of developing a glioma, according to a study by Andersen et al published in the British Journal of Clinical Pharmacology. Study Details While little is known about the causes of...
ATRX Mutation Linked to Brain and Pancreatic Neuroendocrine Tumors May Be Biomarker for Rare Adrenal Tumors
A somatic mutation in the ATRX gene has recently been identified as a potential molecular marker for gliomas, neuroblastomas, and pancreatic neuroendocrine tumors. Now, researchers at the Perelman School of Medicine at the University of Pennsylvania have found that the same mutated gene may serve...
Sputum Biomarker Panel May Help Identify Which Patients With Lung Nodules Have Lung Cancer
Among patients who had an unidentifiable lung nodule detected by a chest computed tomography (CT) scan, testing sputum for a panel of three microRNA (miRNA) biomarkers successfully distinguished early-stage lung cancers from nonmalignant nodules most of the time, according to a study reported by...
Next-Generation Sequencing Uncovers Potential Genetic Drivers of Rare Breast Tumors
A new study from researchers at the University of Michigan Comprehensive Cancer Center characterizes the genetic underpinnings of phyllodes tumors, a rare type of breast tumor. The study offers the first comprehensive analysis of the molecular alterations at work in these tumors, according to Cani...
CPX-351 Receives Fast Track Designation for Secondary Acute Myeloid Leukemia in Elderly Patients
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Celator Pharmaceuticals’ investigational agent CPX-351, a liposomal formulation of cytarabine-daunorubicin, for the treatment of elderly patients with secondary acute myeloid leukemia. The FDA established the...
Two Combination Studies Demonstrate Safety and Survival Benefit for VT-122 in Liver and Pancreatic Cancers
The immunooncology company Vicus Therapeutics announced the presentation of two separate studies demonstrating a safety and survival benefit for VT-122, the company's lead compound, when combined with standard-of-care therapy in patients with advanced liver and pancreatic cancers. Results from both ...
Expanded Analyses of Phase III MM-398 NAPOLI-1 Study Substantiate Positive Results of MM-398 Combined With Fluorouracil/Leucovorin
Additional analyses from the global phase III NAPOLI-1 study of MM-398 (aka PEP02), a nanoliposomal encapsulation of irinotecan, in metastatic pancreatic cancer were presented by Chen et al in an oral session at the 2015 Gastrointestinal Cancers Symposium (Abstract 234). The primary analysis ...
Phase II and III Trials Support First-Line Panitumumab in Combination With FOLFOX in Wild‑Type RAS Metastatic Colorectal Cancer
New data from the phase II PEAK and phase III PRIME studies support the first-line use of panitumumab (Vectibix) in combination with FOLFOX (fluorouracil, leucovorin, oxaliplatin) in patients with wild-type RAS metastatic colorectal cancer. The study results were presented during a poster session...
Modified Pancreatic Cancer Regimen Maintains Effectiveness While Reducing Side Effects and Cost
A simple change to a two-drug therapy for metastatic pancreatic cancer provides similar cancer control while significantly improving quality of life and reducing the cost of care, according to data reported by researchers at the The Ohio State University Comprehensive Cancer Center – Arthur...
Breast Cancer Diagnoses and Survival Outcomes Vary by Race/Ethnicity
Among nearly 375,000 U.S. women diagnosed with invasive breast cancer, the likelihood of diagnosis at an early stage, and survival after stage I diagnosis, varied by race and ethnicity, with much of the difference accounted for by biologic differences, according to a study reported by Iqbal et al...
Study Finds Decreasing Rates of Primary Tumor Resection and Better Survival Among Patients With Advanced Colorectal Cancer
The annual rate of primary tumor removal for stage IV colorectal cancer has decreased since 1988, and the trend toward nonsurgical management of the disease noted in 2001 coincides with the availability of newer chemotherapy and biologic treatments, according to study reported by Hu et al in JAMA...
Combining Newer, More Intensive First-Line Chemotherapy With Bevacizumab Improves Long-Term Outcome in Advanced Colorectal Cancer
Updated results from TRIBE, an Italian phase III study of patients with metastatic colorectal cancer, indicate that FOLFOXIRI (leucovorin, fluorouracil [5-FU], oxaliplatin, irinotecan) chemotherapy in combination with bevacizumab (Avastin) is superior to the standard FOLFIRI (leucovorin, 5-FU,...
Second-Line Ramucirumab Added to Standard Chemotherapy Improves Survival in Patients With Advanced Colorectal Cancer
New findings from an international phase III study of 1,072 patients with advanced colorectal cancer whose disease progressed on or after initial therapy indicate that a combination of the targeted drug ramucirumab (Cyramza) and FOLFIRI (irinotecan, fluorouracil, leucovorin) chemotherapy provides a ...
Chemoradiation Plus Nonsurgical Management of Rectal Cancer Appears Safe, May Offer Better Quality of Life Than Surgery
A retrospective review of clinical data on 145 patients with stage I to III rectal cancer indicates that patients who achieved complete response after treatment with chemoradiation and systemic chemotherapy had similar 4-year survival rates regardless of whether they had immediate surgery or...
Higher Vitamin D Levels Associated With Markedly Improved Survival in Patients With Advanced Colorectal Cancer
A prospective analysis of data from a phase III study of patients newly diagnosed with metastatic colorectal cancer indicates that patients with higher vitamin D levels have better outcomes after treatment with chemotherapy and targeted therapy. The median overall survival for patients with the...
Many Cancer Survivors Have Unmet Physical and Mental Needs Related to Their Disease and Its Treatment
Even decades after being cured, many cancer survivors face physical and mental challenges resulting from their disease and its treatment, according to a new study reported by Burg et al in Cancer. The findings could help clinicians and other experts develop interventions that are tailored to the...
Long-Term Follow-up Shows Favorable Overall Survival Rates With Concurrent Neoadjuvant Chemoradiotherapy Regimens in Rectal Cancer
Patients with locally advanced rectal cancer who receive neoadjuvant radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a 4-year overall survival rate of 85% and 75%, respectively, according to a study reported by Wong et al in the International Journal ...
Oral Human Papillomavirus Infection More Likely to Persist in Older Men
Oral infection with human papillomavirus 16 (HPV16), which is the type of HPV most frequently linked to HPV-driven head and neck cancers, was more likely to persist 12 or more months in men older than 45 than in those younger than 45, according to a study reported by Pierce Campbell et al in...
New Cancer Diagnoses Associated With Increased Risk of Stroke
Patients with new cases of cancer face a heightened risk of stroke in the months immediately following their diagnoses, with that risk escalating with the aggressiveness of their disease, according to a new study from researchers at Weill Cornell Medical College and Memorial Sloan Kettering Cancer...
FDA Grants Fast Track Designation to SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphoma
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Soligenix’s synthetic hypericin (SGX301) development program for the first-line treatment of cutaneous T-cell lymphoma. Fast Track designation is reserved for drugs that demonstrate the potential to address an...
Stereotactic Body Radiation Therapy Plus Chemotherapy Improves Survival Among Patients With Stage IV Lung Cancer
A clinical trial that combined stereotactic body radiation therapy (SBRT) with erlotinib chemotherapy more than doubled survival rates for certain patients with stage IV lung cancer patients, reported Iyengar et al in the Journal of Clinical Oncology. SBRT is a type of radiation therapy in which a ...
Radiation Plus Androgen-Deprivation Therapy Prolongs Survival for Older Men With Prostate Cancer
Adding radiation treatment to androgen-deprivation therapy saves more lives among older men with locally advanced prostate therapy than androgen-deprivation therapy alone, according to a new study reported by Bekelman et al in the Journal of Clinical Oncology. The researchers found that...
More Than 1.5 Million Cancer Deaths Averted During 2 Decades of Dropping Mortality
The American Cancer Society’s annual cancer statistics report found that a 22% drop in cancer mortality over 2 decades led to the avoidance of more than 1.5 million cancer deaths that would have occurred if peak rates had persisted. And while cancer death rates have declined in every state,...
FDA Approves Nivolumab for Advanced Melanoma
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is intended for patients who have been previously treated with ipilimumab...
American Psychosocial Oncology Society Issues Call for 2015 Award Nominations
The American Pyschosocial Oncology Society (APOS) announced today that it is accepting nominations for its 2015 awards. The deadline for submitting nominations is December 31, 2014. These awards will be presented at the World Congress of Psycho-Oncology, to be held July 30 to August 1, 2015. For...
Bisphosphonates May Help Prevent Endometrial Cancer
A new analysis suggests that women who use bisphosphonates have about half the risk of developing endometrial cancer as women who do not use the drugs. The findings by Alford et al, published early online in Cancer, supports other research that has shown an anticancer effect of this type of...
Laparoscopic Surgery for Bladder Cancer Leads to Good Long-Term Cancer Control
Long-term survival rates following laparoscopic surgery for bladder cancer are comparable to those of open surgery, according to a study published in BJU International. The findings, which come from the largest study to date with long-term follow-up after this type of minimally invasive surgery,...
FDA Approves Companion Diagnostic for the Detection of BRCA1/2 Mutations in Ovarian Cancer
Today’s approval by the U.S. Food and Drug Administration (FDA) of olaparib (Lynparza) occurred concurrently with that of a companion diagnostic, BRACAnalysis CDx. This genetic test is designed to detect the presence of mutations in the BRCA genes in blood samples from patients with ovarian...
FDA Approves Olaparib to Treat BRCA-Mutated Advanced Ovarian Cancer
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to olaparib (Lynparza) for women with advanced ovarian cancer with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer, as detected by an FDA-approved test, who have been treated with three ...
Targeted Next-Generation Sequencing Reveals a High Number of Genomic Mutations in Advanced Malignant Plural Mesothelioma
Next-generation sequencing in malignant pleural mesothelioma tumors shows a complex mutational setting with a high number of genetic alterations in genes involved in DNA repair, cell survival, and cell proliferation pathways, according to a study by Lo Iacono et al in the Journal of Thoracic...
Study Identifies Mechanism Behind Genetic Abnormality That Accelerates Growth of Ewing Sarcoma
The genetic abnormality that drives the bone cancer Ewing sarcoma operates through two distinct processes, both activating genes that stimulate tumor growth and suppressing those that should keep cancer from developing. The findings by Riggi et al, published in Cancer Cell, may lead to new...
